{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:37:46Z","timestamp":1780461466823,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00535-025-02333-w","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:02:23Z","timestamp":1768532543000},"page":"386-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of extraintestinal cancer in patients with inflammatory bowel disease: a multicenter retrospective cohort study in Japan"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-8922","authenticated-orcid":false,"given":"Shin","family":"Fujioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Umeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Nishimata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iraha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Sakemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoki","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanae","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Kanmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hotokezaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the IBD-Quality Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2333_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"key":"2333_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10350-006-0848-z","volume":"50","author":"AC von Roon","year":"2007","unstructured":"von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn\u2019s disease. Dis Colon Rectum. 2007;50:839\u201355. https:\/\/doi.org\/10.1007\/s10350-006-0848-z.","journal-title":"Dis Colon Rectum"},{"key":"2333_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","volume":"10","author":"T Jess","year":"2012","unstructured":"Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639\u201345. https:\/\/doi.org\/10.1016\/j.cgh.2012.01.010.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2333_CR4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cgh.2020.08.015","volume":"19","author":"B Lo","year":"2021","unstructured":"Lo B, Zhao M, Vind I, et al. The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2021;19:1117-38 e19. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.015.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2333_CR5","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(09)61302-7.","journal-title":"Lancet"},{"key":"2333_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","volume":"13","author":"DS Kotlyar","year":"2015","unstructured":"Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847-58 e4. https:\/\/doi.org\/10.1016\/j.cgh.2014.05.015. (quiz e48-50).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2333_CR7","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679\u201386. https:\/\/doi.org\/10.1001\/jama.2017.16071.","journal-title":"JAMA"},{"key":"2333_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","volume":"8","author":"MD Long","year":"2010","unstructured":"Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268\u201374. https:\/\/doi.org\/10.1016\/j.cgh.2009.11.024.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2333_CR9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","volume":"141","author":"L Peyrin-Biroulet","year":"2011","unstructured":"Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621-28 e1 5. https:\/\/doi.org\/10.1053\/j.gastro.2011.06.050.","journal-title":"Gastroenterology"},{"key":"2333_CR10","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","volume":"21","author":"U Kopylov","year":"2015","unstructured":"Kopylov U, Vutcovici M, Kezouh A, et al. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21:1847\u201353. https:\/\/doi.org\/10.1097\/MIB.0000000000000457.","journal-title":"Inflamm Bowel Dis"},{"key":"2333_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","volume":"143","author":"MD Long","year":"2012","unstructured":"Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390-9 e1. https:\/\/doi.org\/10.1053\/j.gastro.2012.05.004.","journal-title":"Gastroenterology"},{"key":"2333_CR12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/ajg.2016.239","volume":"111","author":"LH Wang","year":"2016","unstructured":"Wang LH, Yang YJ, Cheng WC, et al. Higher risk for hematological malignancies in inflammatory bowel disease: a nationwide population-based study in Taiwan. Am J Gastroenterol. 2016;111:1313\u20139. https:\/\/doi.org\/10.1038\/ajg.2016.239.","journal-title":"Am J Gastroenterol"},{"key":"2333_CR13","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1097\/MIB.0000000000001240","volume":"23","author":"J So","year":"2017","unstructured":"So J, Tang W, Leung WK, et al. Cancer risk in 2621 Chinese patients with inflammatory bowel disease: a population-based cohort study. Inflamm Bowel Dis. 2017;23:2061\u20138. https:\/\/doi.org\/10.1097\/MIB.0000000000001240.","journal-title":"Inflamm Bowel Dis"},{"key":"2333_CR14","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjx040","volume":"11","author":"YS Jung","year":"2017","unstructured":"Jung YS, Han M, Park S, et al. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a nationwide population-based study. J Crohns Colitis. 2017;11:954\u201362. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx040.","journal-title":"J Crohns Colitis"},{"key":"2333_CR15","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/jgh.12189","volume":"28","author":"Y Yano","year":"2013","unstructured":"Yano Y, Matsui T, Hirai F, et al. Cancer risk in Japanese Crohn\u2019s disease patients: investigation of the standardized incidence ratio. J Gastroenterol Hepatol. 2013;28:1300\u20135. https:\/\/doi.org\/10.1111\/jgh.12189.","journal-title":"J Gastroenterol Hepatol"},{"key":"2333_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489\u2013526. https:\/\/doi.org\/10.1007\/s00535-021-01784-1.","journal-title":"J Gastroenterol"},{"key":"2333_CR17","unstructured":"Cancer statistics. Cancer information service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare). https:\/\/ganjoho.jp\/reg_stat\/index.html."},{"key":"2333_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00535-018-1482-y","volume":"54","author":"S Yasukawa","year":"2019","unstructured":"Yasukawa S, Matsui T, Yano Y, et al. Crohn\u2019s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan. J Gastroenterol. 2019;54:42\u201352. https:\/\/doi.org\/10.1007\/s00535-018-1482-y.","journal-title":"J Gastroenterol"},{"key":"2333_CR19","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z","volume":"91","author":"C Bernstein","year":"2001","unstructured":"Bernstein C, Blanchard J, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854\u201362. https:\/\/doi.org\/10.1002\/1097-0142(20010215)91:4%3c854::aid-cncr1073%3e3.0.co;2-z.","journal-title":"Cancer"},{"key":"2333_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/gut.2004.051771","volume":"54","author":"J Askling","year":"2005","unstructured":"Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617\u201322. https:\/\/doi.org\/10.1136\/gut.2004.051771.","journal-title":"Gut"},{"key":"2333_CR21","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/ajg.2013.249","volume":"108","author":"T Jess","year":"2013","unstructured":"Jess T, Horvath-Puho E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108:1869\u201376. https:\/\/doi.org\/10.1038\/ajg.2013.249.","journal-title":"Am J Gastroenterol"},{"key":"2333_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/ajg.2016.304","volume":"111","author":"H Cheddani","year":"2016","unstructured":"Cheddani H, Dauchet L, Fumery M, et al. Cancer in elderly onset inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2016;111:1428\u201336. https:\/\/doi.org\/10.1038\/ajg.2016.304.","journal-title":"Am J Gastroenterol"},{"key":"2333_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/ecco-jcc\/jjab199","volume":"16","author":"Y Kakuta","year":"2022","unstructured":"Kakuta Y, Iwaki H, Umeno J, et al. Crohn\u2019s disease and early exposure to thiopurines are independent risk factors for mosaic chromosomal alterations in patients with inflammatory bowel diseases. J Crohns Colitis. 2022;16:643\u201355. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab199.","journal-title":"J Crohns Colitis"},{"key":"2333_CR24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","volume":"17","author":"H Gordon","year":"2023","unstructured":"Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2023;17:827\u201354. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac187.","journal-title":"J Crohns Colitis"},{"key":"2333_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2036.2011.04969.x","volume":"35","author":"A Sonnenberg","year":"2012","unstructured":"Sonnenberg A, Genta RM. Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:469\u201376. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04969.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"2333_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/ecco-jcc\/jjv032","volume":"9","author":"A Algaba","year":"2015","unstructured":"Algaba A, Guerra I, Marin-Jimenez I, et al. Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohns Colitis. 2015;9:326\u201333. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv032.","journal-title":"J Crohns Colitis"},{"key":"2333_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/ecco-jcc\/jjz204","volume":"14","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Uda A, Udagawa E, et al. Lack of increased risk of lymphoma by thiopurines or biologics in Japanese patients with inflammatory bowel disease: a large-scale administrative database analysis. J Crohns Colitis. 2020;14:617\u201323. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz204.","journal-title":"J Crohns Colitis"},{"key":"2333_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/ibd\/izz155","volume":"26","author":"L Biancone","year":"2020","unstructured":"Biancone L, Armuzzi A, Scribano ML, et al. Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD study. Inflamm Bowel Dis. 2020;26:450\u20139. https:\/\/doi.org\/10.1093\/ibd\/izz155.","journal-title":"Inflamm Bowel Dis"},{"key":"2333_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41395-018-0360-9","volume":"114","author":"S Scharl","year":"2019","unstructured":"Scharl S, Barthel C, Rossel JB, et al. Malignancies in inflammatory bowel disease: frequency, incidence and risk factors-results from the Swiss IBD cohort study. Am J Gastroenterol. 2019;114:116\u201326. https:\/\/doi.org\/10.1038\/s41395-018-0360-9.","journal-title":"Am J Gastroenterol"},{"key":"2333_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/ecco-jcc\/jjaa172","volume":"15","author":"K Matsuoka","year":"2021","unstructured":"Matsuoka K, Igarashi A, Sato N, et al. Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016. J Crohns Colitis. 2021;15:358\u201366. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa172.","journal-title":"J Crohns Colitis"},{"key":"2333_CR31","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ajg.2017.96","volume":"112","author":"M Chaparro","year":"2017","unstructured":"Chaparro M, Ramas M, Benitez JM, et al. Extracolonic cancer in inflammatory bowel disease: data from the GETECCU Eneida registry. Am J Gastroenterol. 2017;112:1135\u201343. https:\/\/doi.org\/10.1038\/ajg.2017.96.","journal-title":"Am J Gastroenterol"},{"key":"2333_CR32","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","volume":"63","author":"L Beaugerie","year":"2014","unstructured":"Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416\u201323. https:\/\/doi.org\/10.1136\/gutjnl-2013-305763.","journal-title":"Gut"},{"key":"2333_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","volume":"14","author":"J Axelrad","year":"2016","unstructured":"Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:58\u201364. https:\/\/doi.org\/10.1016\/j.cgh.2015.07.037.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2333_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cgh.2020.10.007","volume":"20","author":"A Vedamurthy","year":"2022","unstructured":"Vedamurthy A, Gangasani N, Ananthakrishnan AN. Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: a retrospective cohort study. Clin Gastroenterol Hepatol. 2022;20:88\u201395. https:\/\/doi.org\/10.1016\/j.cgh.2020.10.007.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2333_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","volume":"9","author":"DS Kotlyar","year":"2011","unstructured":"Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36-41 e1. https:\/\/doi.org\/10.1016\/j.cgh.2010.09.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2333_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/apt.15538","volume":"51","author":"T Card","year":"2020","unstructured":"Card T, Ungaro R, Bhayat F, et al. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. Aliment Pharmacol Ther. 2020;51:149\u201357. https:\/\/doi.org\/10.1111\/apt.15538.","journal-title":"Aliment Pharmacol Ther"},{"key":"2333_CR37","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/jgh.15806","volume":"37","author":"B Hasan","year":"2022","unstructured":"Hasan B, Tandon KS, Miret R, et al. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy. J Gastroenterol Hepatol. 2022;37:1016\u201321. https:\/\/doi.org\/10.1111\/jgh.15806.","journal-title":"J Gastroenterol Hepatol"},{"key":"2333_CR38","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/ibd\/izaa199","volume":"27","author":"GR Lichtenstein","year":"2021","unstructured":"Lichtenstein GR, Rogler G, Ciorba MA, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancy (excluding nonmelanoma skin cancer) events across the ulcerative colitis clinical program. Inflamm Bowel Dis. 2021;27:816\u201325. https:\/\/doi.org\/10.1093\/ibd\/izaa199.","journal-title":"Inflamm Bowel Dis"},{"key":"2333_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ibd\/izab056","volume":"28","author":"BE Sands","year":"2022","unstructured":"Sands BE, Long MD, Reinisch W, et al. Tofacitinib for the treatment of ulcerative colitis: analysis of nonmelanoma skin cancer rates from the ulcerative colitis clinical program. Inflamm Bowel Dis. 2022;28:234\u201345. https:\/\/doi.org\/10.1093\/ibd\/izab056.","journal-title":"Inflamm Bowel Dis"},{"key":"2333_CR40","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02333-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02333-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02333-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:06:15Z","timestamp":1779375975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02333-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2333"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02333-w","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JU reports lecture fees from AbbVie G.K. RS reports lecture fees from AbbVie G.K., Takeda Pharmaceutical Co., Ltd. FH reports grants or contracts from AbbVie G.K., Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., MSD K.K., and lecture fees from AbbVie G.K., EA Pharma Co., Ltd, Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Takeda Co., Ltd. ME reports grants or contracts from Kyorin Pharmaceutical Co. Ltd, Alfresa Pharma Corporation, and lecture fees from AbbVie G.K., Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd, Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd, Pfizer Japan Inc., Gilead Sciences Inc., Bristol Myers Squibb. Other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}